BackPalvella Therapeutics Overview
Palvella Therapeutics, Inc.

Palvella Therapeutics Target Price

Analysts' average 12-month price target for Palvella Therapeutics is $230.

Get informed when a big investor buys or sells

+ Follow

Share Price

$157.24

Average Target Price

$232.2547.7% upside

4 analysts in the last 4 months

High: $270 | Low: $207

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-05Truist Financial$20731.6% upsideOpen
2026-08-05Canaccord Genuity$23247.5% upsideOpen
2026-07-22H.C. WainwrightAndrew Fein$27071.7% upsideOpen
2026-05-12Stephens$22039.9% upsideOpen
2026-02-24Truist Financial$21033.6% upsideOpen
2026-02-24Chardan Capital$21033.6% upsideOpen
2026-02-24Stifel Nicolaus$25059% upsideOpen
2026-02-24H.C. Wainwright$25562.2% upsideOpen
2026-01-07Mizuho Securities$20530.4% upsideOpen
2025-12-16Canaccord GenuityWhitney Ijem$20429.7% upsideOpen
2025-12-16Raymond JamesRyan Deschner$19322.7% upsideOpen
2025-12-15Chardan Capital$17410.7% upsideOpen
2025-12-15BTIGJeff Mukherjee$19222.1% upsideOpen
2025-12-15Truist Financial$19020.8% upsideOpen
2025-12-15UBSCatherine Novack$1439.1% downsideOpen
2025-12-15H.C. Wainwright$20027.2% upsideOpen
2025-12-15Cantor Fitzgerald$21033.6% upsideOpen
2025-12-15Oppenheimer$20027.2% upsideOpen
2025-12-11H.C. WainwrightAndrew Fein$19020.8% upsideOpen
2025-12-05BTIG$1676.2% upsideOpen
2025-12-04Craig-HallumAlbert Lowe$17511.3% upsideOpen
2025-11-24Stifel NicolausSamimy Annabel$1457.8% downsideOpen
2025-11-19Raymond James$1439.1% downsideOpen
2025-11-06Cantor Fitzgerald$20027.2% upsideOpen
2025-10-09Canaccord Genuity$9042.8% downsideOpen
2025-10-07Cantor Fitzgerald$12023.7% downsideOpen
2025-10-02Truist FinancialDanielle Brill$8049.1% downsideOpen
2025-09-25H.C. Wainwright$9539.6% downsideOpen
2025-09-24Stifel NicolausAnnabel Samimy$8049.1% downsideOpen
2025-09-09Oppenheimer$8545.9% downsideOpen
2025-08-15H.C. WainwrightAndres Maldonado$7552.3% downsideOpen
2025-08-05Raymond James$5465.7% downsideOpen
2025-05-16Canaccord GenuityWhitney Ijem$5266.9% downsideOpen
2025-03-25Stifel NicolausAnnabel Samimy$4571.4% downsideOpen
2024-12-18Cantor FitzgeraldJosh Schimmer$3080.9% downsideOpen

Palvella Therapeutics (PVLA) FAQ

Palvella Therapeutics posts a target price of $230. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $230 for PVLA means covering analysts, on average, see the stock 47.7% upside of $157.24 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for PVLA's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Palvella Therapeutics's other metric pages and overview cover the third.

Judging Palvella Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $230 here, then scan peer and history charts to see if the gap is persistent.